RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

PharmaResearch Co EBIT 2024

PharmaResearch Co EBIT

116.68 B KRW

PharmaResearch Co Dividend yield

0.69 %

Ticker

214450.KQ

ISIN

KR7214450009

In 2024, PharmaResearch Co's EBIT was 116.68 B KRW, a 26.47% increase from the 92.26 B KRW EBIT recorded in the previous year.

The PharmaResearch Co EBIT history

YEAREBIT (undefined KRW)
2025e133.04
2024e116.68
202392.26
202265.92
202152.49
202033.43
201919.06
20188.71
201714.84
201614.11
201516.09
201411.41
20137.21

PharmaResearch Co Aktienanalyse

What does PharmaResearch Co do?

PharmaResearch Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing PharmaResearch Co's EBIT

PharmaResearch Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PharmaResearch Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PharmaResearch Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PharmaResearch Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PharmaResearch Co Stock

How much did PharmaResearch Co achieve in EBIT for the current year?

In the current year, PharmaResearch Co has achieved an EBIT of 116.68 B KRW.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company PharmaResearch Co.

How has the EBIT of PharmaResearch Co developed in recent years?

The EBIT of PharmaResearch Co has increased by 26.467% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company PharmaResearch Co?

The EBIT of PharmaResearch Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does PharmaResearch Co pay?

Over the past 12 months, PharmaResearch Co paid a dividend of 950 KRW . This corresponds to a dividend yield of about 0.69 %. For the coming 12 months, PharmaResearch Co is expected to pay a dividend of 1,044.52 KRW.

What is the dividend yield of PharmaResearch Co?

The current dividend yield of PharmaResearch Co is 0.69 %.

When does PharmaResearch Co pay dividends?

PharmaResearch Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of PharmaResearch Co?

PharmaResearch Co paid dividends every year for the past 11 years.

What is the dividend of PharmaResearch Co?

For the upcoming 12 months, dividends amounting to 1,044.52 KRW are expected. This corresponds to a dividend yield of 0.76 %.

In which sector is PharmaResearch Co located?

PharmaResearch Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von PharmaResearch Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PharmaResearch Co from 4/18/2024 amounting to 950 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did PharmaResearch Co pay the last dividend?

The last dividend was paid out on 4/18/2024.

What was the dividend of PharmaResearch Co in the year 2023?

In the year 2023, PharmaResearch Co distributed 660 KRW as dividends.

In which currency does PharmaResearch Co pay out the dividend?

The dividends of PharmaResearch Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PharmaResearch Co

Our stock analysis for PharmaResearch Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaResearch Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.